Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of AD-208 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating efficacy and safety of AD-208 for androgenetic alopecia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• AD-208

Snippet

Sponsor: Addpharma Inc. | Conditions: Androgenetic Alopecia | Phase 3 | Status: COMPLETED